Category Archives: Uncategorized

Combining Rituximab with Belimumab in Severe Lupus

Our next #RheumJC session will be Thursday, April 26th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recent Journal of Autoimmunity article: The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Cardiovascular Safety of Febuxostat or Allopurinol

Our next #RheumJC session will be Thursday, March 29th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recent New England Journal of Medicine article: Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Abatacept for Treatment of RA-ILD

Our next #RheumJC session will be Thursday, February 22nd at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recent Seminars in Arthritis & Rheumatism article: Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Stem-Cell Transplantation for Scleroderma

Our next #RheumJC session will be Thursday, January 25th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recent New England Journal of Medicine Article: Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Favorite Abstracts from the 2017 ACR Annual Meeting

Our next #RheumJC session will be Thursday, November 30th at 10pm Eastern Time (click here to find this in your time zone).

We’ll be discussing four of our favorite abstracts from the recent #ACR17 Meeting in San Diego:

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis

Our next #RheumJC session will be Thursday, October 26th.

We’ll be discussing the article Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis epublished in Arthritis Care & Research

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

internal #RheumJC poll of #ACR16 abstracts

Internal #RheumJC poll - choose as many as you would like

  • 3028 - A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (10%, 5 Votes)
  • 911 - Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (10%, 5 Votes)
  • 1955 - Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (10%, 5 Votes)
  • 2987 - Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study (8%, 4 Votes)
  • 1725 - Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (6%, 3 Votes)
  • 3225 - Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with RA (6%, 3 Votes)
  • 86 - Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture (6%, 3 Votes)
  • 3169 - Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study (6%, 3 Votes)
  • 1957 - No Increased Risk of Chronic Kidney Disease with Allopurinol Use (6%, 3 Votes)
  • 2983 - Efficacy and Safety of Tofacitinib, an Oral JAK Inhibitor, or Adalimumab in Patients with Active PsA and an Inadequate Response to Conventional Synthetic Dmards: A RCT Phase 3 Trial. (4%, 2 Votes)
  • 604 - Sustained Efficacy/Comparable Safety/Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with RA (4%, 2 Votes)
  • 597 - Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015 (4%, 2 Votes)
  • 559 - Comparison of MD-HAQ-Based and PROMIS 29-Based RAPID3 for Assessing RA Disease Activity (4%, 2 Votes)
  • 10L - Efficacy and Safety of Tofacitinib, an Oral JAK Inhibitor, in Patients with Active PsA and an Inadequate Response to TNF Inhibitors: OPAL Beyond, a RCT, Phase 3 Trial (4%, 2 Votes)
  • 2001 - Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections (2%, 1 Votes)
  • 969 - Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial (2%, 1 Votes)
  • 1047 - Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability. (2%, 1 Votes)
  • 1586 - Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional DMARDs: A United States Subpopulation Analysis from Two Phase 3 Trials (2%, 1 Votes)

Total Voters: 7

Loading ... Loading ...